Index Intelligence

5 high priority 9 medium 14 total filings

S&P 500 Technology Sector SEC Filings — April 13, 2026

Across 14 filings in the S&P 500 Technology stream, institutional 13F-HRs reveal overwhelming conviction in core tech leaders, with NVDA topping holdings in 4/5 reports (total ~$750M+ exposure), AAPL/MSFT/AMZN following closely in multi-billion portfolios, signaling sustained AI/semi/mega-cap strength amid Q1 2026 positioning. Palo Alto Networks (PANW) stands out with a bullish long-term lease extension for 290k sq ft to 2040 ($13M-$16M annual rent), underscoring cybersecurity expansion. Non-tech filings show mixed trends: Pineapple Financial bolstered balance sheet with $72M funding despite $23M crypto loss (-5.5% rev YoY), Jewett-Cameron posted +4.7-16.4% sales growth but -83.8% gross profit H1 YoY driving $5.2M loss. Proxy materials for Dime/Genco neutral, Pershing Square advances PSUS IPO and $2.1B Q2 2026 M&A for AUM growth, while Replimune faces 2nd FDA CRL setback. Portfolio-level: Revenue growth in 2/4 10-Qs but margin compression/losses dominate small caps; tech signals bullish via institutions/PANW.

5 high priority 8 medium 13 total filings

Nasdaq 100 Stocks SEC Filings — April 13, 2026

Across 13 SEC filings from NASDAQ-100 constituents and related entities, key themes include divergent financial performances with revenue growth in AI and trading sectors offset by sharp losses from crypto impairments and operational declines; biotech faces regulatory hurdles while proxies signal active governance seasons for banks and shipping. Period-over-period trends show 2/5 financial reporters with revenue growth (AITX +26% YoY, Jewett-Cameron +16.4% YoY Q3) but widespread margin compression (Jewett gross profit -83.8% YoY half-year, Pineapple expenses +820% YoY due to $23M crypto loss) and net losses expanding (Jewett net loss $5.2M half-year vs prior, Pineapple $25.9M). Institutional 13F filings reveal heavy concentration in megacap tech (NVDA, AAPL, MSFT topping portfolios totaling billions), indicating sustained conviction amid volatility. Positive catalysts include board strengthening at CMC and balance sheet fortification at Pineapple via $52M+ financing; risks dominate in crypto (Intchains negative cash flows, no dividends) and biotech (Replimune second FDA CRL). Portfolio-level implications favor selective longs in AI/growth stories and caution on speculative crypto/biotech exposures ahead of proxy votes and earnings.

27 high priority 23 medium 50 total filings

S&P 500 Financials Sector SEC Filings — April 13, 2026

Across 50 filings from the USA S&P 500 Financials intelligence stream (broadly including banks, insurers, asset managers, and adjacent sectors), dominant themes include robust M&A activity (e.g., Somnigroup-LEG $2.5B all-stock deal, Clear Channel $2.43/share buyout), IPO preparations (Alamar Biosciences, Kailera Therapeutics), and mixed financial results with revenue growth averaging ~60% YoY in reporting small caps (e.g., Alamar 195%, OriginClear 55%) offset by persistent margin compression (avg -200bps in 4/7 detailed firms) and net losses. Biotech/healthcare filings show positive trial catalysts (IDEAYA PFS HR 0.42, Spyre RHI -9.2 pts), while operational disruptions like contract losses (Ameriguard 58% revenue hit) and regulatory setbacks (Replimune 2nd CRL) temper optimism. Capital allocation leans shareholder-friendly with dividend hikes (American States +8.3%) and buybacks (News Corp $1B program), but Nasdaq compliance risks (Sow Good equity < $2.5M) and leadership changes signal caution. Portfolio-level trends reveal 8/15 revenue reporters growing >20% YoY, yet 5/7 margins declining amid SG&A surges; forward catalysts cluster in H2 2026 (FDA NDAs, Phase 3 readouts, merger closes). Overall, actionable alpha lies in M&A arbitrage and biotech turnarounds, with financials showing stable but unexciting EPS growth (e.g., ChoiceOne proxy neutral).

S&P 500 Consumer Staples Sector SEC Filings — April 13, 2026

Across the 50 filings in the USA S&P 500 Consumer Staples intelligence stream, direct staples exposure is limited to Conagra Brands (CEO transition) and Coca-Cola Europacific Partners (share repurchases), amid a broader mix of proxy statements, financial reports, and M&A updates; overarching themes include active proxy season with 15+ DEF/DEFA14A filings seeking director elections and compensation approvals, and resilient revenue growth in small-caps averaging +77% YoY where reported (Envirotech +218%, OriginClear +55%, Elite Express +16%). Period-over-period trends show 6/12 financial filings with YoY revenue gains but mixed margins (e.g., AITX gross margins +1000bps to 71%, Kopin cost/revenue 84.2% stable), offset by cash drains (Elite Express cash -95% QoQ to $68K) and losses (Edgemode net loss +1450% to $24.6M). Capital allocation leans shareholder-friendly with dividends up (Farmer Mac +7% YoY quarterly, KKR FS Income $0.225/share monthly), buybacks (Teleflex $1B from $1.8B divestiture proceeds), and repurchases (CCEP 273K shares). Forward-looking catalysts cluster in H2 2026 (Teleflex divest closes, Perella Weinberg acquisition) and Q2 2026 (Diamond Hill merger), with positive sentiment in 12/50 filings driven by M&A and leadership stability. Portfolio-level patterns flag staples-adjacent strength in food/agri (Conagra $12B sales, Farmer Mac 116% ROE) versus risks in delisting threats and lawsuits, implying selective buying opportunities pre-catalysts.

S&P 500 Industrials Sector SEC Filings — April 13, 2026

Proxy season dominates the 50 filings with over 20 DEF 14A/DEFA14A announcements for annual meetings clustered in May-June 2026, focusing on director elections, auditor ratifications, and compensation votes, mostly neutral sentiment but highlighting governance strengths like 100% board independence at Farmer Mac. Financial disclosures reveal mixed trends: Bancorp assets +8.0% YoY to $9.4B, net income +4.6% to $228M, ROE 29% (up from 27%); Farmer Mac record 116% ROE, book value $112.77 (+YoY), dividend +7%; contrasted by TOFUTTI sales -11.8% YoY to $7.8M, op loss +27.5%; Edgemode net loss ballooned to $24.6M from $1.6M, liabilities x4.2 to $20.1M. Positive catalysts include Leggett & Platt $2.5B all-stock acquisition (0.1455x exchange ratio), IDEAYA Phase 2/3 PFS 6.9mo vs 3.1mo (HR 0.42), Diamondback Q1 hedged oil $72.53/bbl with $133M derivative gain, AITX FY26 rev +26% to $7.75M/margins +10pts to 71%. 13F-HR filings (12 total) show institutional heavy tilt to tech (Apple/MSFT/NVDA top across $10B+ AUM), minimal Industrials exposure. Industrials-specific: Caterpillar director nominee Aug 1, Patterson-UTI LTIP expansion +28.9M shares (overhang to 11.3%), Genco Shipping proxy solicitation. Overall neutral-to-mixed sentiment (avg materiality 5.8/10), with capital allocation favoring dividends/equity plans amid limited M&A/insider data.

1 high priority 6 medium 7 total filings

S&P 500 Energy Sector SEC Filings — April 13, 2026

Across 7 filings in the S&P 500 Energy intelligence stream, 5 neutral 13F-HR reports from advisors (Whalen Wealth, Chesley Taft, Global X Japan, MKD Wealth, John Brooker) reveal snapshot holdings as of March 31, 2026, heavily weighted toward tech giants (Apple, NVIDIA, Broadcom) and ETFs with no period-over-period comparisons, changes, or energy-specific allocations disclosed, signaling institutional caution or underweight in energy. Key positive: Marathon Petroleum (MPC) secured a new $5B revolving credit agreement on April 7, 2026, with favorable tiered pricing (e.g., Level I Term SOFR Spread 1.000%) and standard covenants, enhancing liquidity without issues (positive sentiment, materiality 9/10). Critical negative: Southern Copper (SCCO) announced unexpected CEO/President Oscar Gonzalez Rocha passing on April 7, 2026, with successor planned soon (negative sentiment, materiality 9/10). No YoY/QoQ trends, insider trades, capital allocation shifts, M&A, or scheduled events across filings; portfolio-level pattern shows diversified managers favoring tech/ETFs (e.g., Apple top holding in 5/5 13Fs) over energy, implying sector underperformance relative to broader market.

22 high priority 28 medium 50 total filings

Dow Jones 30 Stocks SEC Filings — April 13, 2026

Across 50 SEC filings from April 13, 2026, primarily involving non-DJ30 names despite the stream focus, dominant themes include a surge in proxy statements (DEF 14A/DEFA14A) for May 2026 annual meetings (e.g., Kyverna, First Busey, Dime Community), board changes/retirements (Independent Bank, 5E Advanced Materials, Caterpillar), and SPAC/M&A activity (Investcorp AI $220M deal, Spring Valley fusion tech, Brag House merger approval). Period-over-period trends show pockets of strength like Envirotech sales +218% YoY to $5.9M, Civeo Australian revenue $460M (72% total, EBITDA +10% YoY), Bancorp assets +8% to $9.4B/net income +4.6% to $228M/ROE +2pp to 29%, offset by weaknesses such as Pineapple revenue -5.5% YoY to $1.4M/huge $26M net loss from crypto, Intchains ongoing losses/negative cash flows. Capital allocation highlights include Franklin Financial dividend +3% YoY to $0.34/share, Civeo $54M buyback (17% shares), Diamondback debt tenders; forward-looking catalysts cluster in biotech (Kyverna BLA H1 2026) and fusion/SPACs. Mixed sentiment prevails with Nasdaq compliance strains (Veea transfer to Capital Market), but positive M&A momentum and derivative gains (Diamondback $133M Q1) signal selective opportunities amid governance churn.

20 high priority 30 medium 50 total filings

S&P 500 Consumer Discretionary Sector SEC Filings — April 13, 2026

Across 50 filings primarily from diverse sectors but focused on S&P 500 Consumer Discretionary context, proxy statements (DEF 14A/DEFA14A) dominate with 12+ companies gearing up for May-June 2026 annual meetings, signaling governance focus amid mixed financials. Period-over-period trends reveal revenue growth in 7/15 financial reporters (e.g., Marti +109% YoY to $39M, Arts-Way +29% YoY sales, AITX +26% FY2026 prelim), but declines in 5 (e.g., New Fortress -36% YoY revenues, TOFUTTI -11.8% sales), with margin improvements in 4 (Marti 61% gross, AITX 71%) offset by compressions (FB Financial NIM -4 bps QoQ). Capital allocation leans bullish with dividend hikes (Franklin +3% YoY, Farmer Mac +7%), Teleflex's $1B buyback from $1.8B divest proceeds, and MarketWise affirming $300M FY2026 billings/$1.80/share div. 20+ 13F-HR filings show persistent institutional overweight in tech/ETFs (Apple/NVDA top holdings across 15+ filers), implying conviction in mega-caps. Insider activity sparse but delinquent reports at F&M Bank flag minor concerns; forward-looking catalysts cluster around AGMs and Q1 earnings (e.g., MarketWise May 7). Overall, portfolio-level trends favor growth in niche consumer plays (golf, retail) but caution on energy/mobility volatility, with actionable buybacks/divs enhancing shareholder returns now.

12 high priority 38 medium 50 total filings

S&P 500 Healthcare Sector SEC Filings — April 13, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (though many span financials, industrials, and biotechs), overarching themes include robust capital raises via PIPEs, convertible notes, and offerings (e.g., Pineapple $53M financing, Newton $1.35M notes, Dare $17.35M units), offsetting revenue pressures in 7/15 companies with financials (avg revenue decline -20% YoY where reported, like New Fortress -36.2%, Lexaria -88.5%). Period-over-period trends show mixed results: loan/deposit growth in banks (FB Financial +28% YoY loans), margin compression (Digital Ally 23% to 10%, FB NIM 3.98% to 3.94% QoQ), and biotech positives (IDEAYA PFS 6.9 vs 3.1 months). Institutional 13F-HR filings (20/50) reveal heavy tech concentration (Apple/Nvidia top in 15+ portfolios, avg $50M+ positions), signaling conviction in megacaps amid volatility. Critical developments: IDEAYA's Phase 2/3 success flags H2 2026 NDA catalyst; capital allocation favors buybacks (Civeo 17% shares) and dividends (Franklin +3% YoY). Portfolio-level patterns highlight small-cap financing resilience but operational losses (avg net loss improvement in 4/8 loss-makers), with healthcare biotechs outperforming on trials/IP (IDEAYA, Catalyst Crew). Market implications: Opportunities in biotech catalysts and undervalued raises, risks in quorum failures and cyber incidents.

9 high priority 3 medium 12 total filings

S&P 500 Technology Sector SEC Filings — April 10, 2026

Across 12 filings in the USA S&P 500 Technology stream (broadly including software, solar tech, biotech, and adjacent), proxy statements dominate (7/12) signaling governance focus ahead of May 2026 annual meetings, while financial reports show mixed performance with revenue declines averaging -7% YoY in key reporters (Canadian Solar -6.6%, Cumulus Media -10.3% FY, Apple iSports 0%) offset by pockets of growth (Simulations Plus +8.3% Q1 YoY). Margin trends are resilient in some (Canadian Solar gross margin +170bps to 18.3%, Simulations Plus net income +47.5% Q1 YoY), but broader pressures evident in widening losses (Canadian Solar net loss from profit, Apple iSports loss doubled to $6.4M). No widespread insider buying/selling, but Immunic's CEO retention bonus ($670K) amid leadership transition flags execution risks; Cumulus Media's Chapter 11 bankruptcy filing is a sector outlier amid debt distress. Capital allocation leans toward equity incentives and ATM expansions (AIM ImmunoTech), with no major dividends/buybacks noted. Upcoming proxies offer voting catalysts, but deteriorating cash flows (Cumulus ops cash use $21M, Simulations cash equiv -17% QoQ) underscore liquidity watchpoints, tilting sector sentiment mixed/neutral with bearish undertones in revenue/margins.

11 high priority 7 medium 18 total filings

Nasdaq 100 Stocks SEC Filings — April 10, 2026

Across 18 NASDAQ-100 related filings from April 10, 2026, proxy season dominates with 7 filings (DEF 14A/DEFA14A) signaling upcoming AGMs in May 2026 for director elections, equity incentive plans, and auditor ratifications, reflecting governance focus amid equity comp expansions. Financial results show mixed trends: Simulations Plus delivered strong Q1 FY2026 revenue +8.3% YoY and net income +47.5% YoY, while Canadian Solar's FY2025 revenue fell 6.6% YoY but gross margins expanded +160 bps to 18.3%; contrasts sharply with Cumulus Media's FY2025 revenue -10.3% YoY and Chapter 11 filing. Biotech and AI sectors shine with clinical progress (MetaVia dosing milestone), product expansions (AITX RAD to 30 units), and leadership retention/incentives (Alphabet exec PSUs/GSUs worth $34M-$48M each, Immunic CEO bonus). No widespread insider selling noted, but option grants and equity awards indicate management alignment. Capital allocation leans toward equity incentives over dividends/buybacks, with operational cash improvements in Simulations Plus (+142% YoY) and Canadian Solar (less cash burn). Portfolio-level, 3/5 financial reports show profitability gains despite revenue softness, but media sector distress (Cumulus EBITDA -37.1% YoY) warrants caution; catalysts cluster in late May AGMs.

28 high priority 22 medium 50 total filings

S&P 500 Financials Sector SEC Filings — April 10, 2026

Across the 50 filings, a dominant theme is the ramp-up to proxy season with 15+ AGMs scheduled in May 2026 (e.g., Plains GP/PAA May 20, Riley May 12, Vontier June 4), featuring routine director elections, auditor ratifications, and advisory pay votes passing overwhelmingly where reported. SPAC and M&A activity surges positively, including Constellation/US Elemental $500M combo (H2 2026 close), Willow Lane/Boost Run EGM Apr 30, and Abra/New Providence crypto merger webinar highlighting Bitcoin at $72k outperforming gold. Period-over-period trends show mixed financial health: stark declines like Li Auto revenues -22.3% YoY and net income -86%, Qudian revenues -81.1% YoY but net income +673% on non-op gains, offset by positives like Riley equity +22% YoY, debt -32%, dividend +5%, and $100M buyback. Capital allocation leans shareholder-friendly with News Corp $1B repurchase, Hecla full $263M note redemption for unencumbered balance sheet, and Onfolio share increase to 300M enabling flexibility. Sentiment skews neutral/positive (70%+), but outliers flag China exposure risks (Li Auto, Qudian) and cost pressures (Retractable workforce cut). Portfolio-level, 4/7 quantifiable trends indicate revenue weakness in non-US ops (-20-80% YoY) but balance sheet strengthening via debt paydowns/deals; implications favor monitoring May catalysts for governance stability and H2 M&A unlocks in SPACs/energy.

26 high priority 24 medium 50 total filings

S&P 500 Consumer Staples Sector SEC Filings — April 10, 2026

Across 50 filings from the USA S&P 500 Consumer Staples intelligence stream (despite diverse inclusions like energy, mining, and SPACs), a dominant theme is proxy season preparation with 20+ DEF 14A/DEFA14A filings highlighting robust 2025 performance, including average revenue growth of ~35% YoY where reported (e.g., Hecla +53%, ClearSign +44%, Garrett + strong sales), deleveraging (Hecla debt -50% YoY), and capital returns via buybacks/dividends (Garrett $208M repurchases, Welltower dividend +10.4%). Period-over-period trends show NOI/margin expansion in outperformers (Welltower 14.1% YoY NOI, Garrett 14.2% Adj EBIT margin) but pockets of weakness like Angel Studios Q1 2026 EBITDA loss $(4-6)M despite $105-109M revenue guidance. Critical developments include SPAC mergers (Constellation $500M equity value, H2 2026 close), spin-offs (Honeywell Aerospace Q3 2026), and auditor changes, signaling portfolio-level focus on growth investments and shareholder value amid positive sentiment in 60% of high-materiality filings. Market implications point to near-term catalysts from May 2026 AGMs, with relative outperformance in capital allocators vs. ongoing loss-makers like TV Channels (losses narrowing -5% YoY but deepening deficit).

31 high priority 19 medium 50 total filings

S&P 500 Industrials Sector SEC Filings — April 10, 2026

Across 50 filings from S&P 500 Industrials and adjacent sectors, proxy statements dominate (e.g., DEF 14A/DEFA14A for Honeywell, Hecla, Garrett Motion, DuPont), highlighting strong 2025 recaps with revenue growth in outliers like Hecla Mining (+53% YoY to $1.4B) and Garrett Motion ($3.58B sales), alongside capital returns via buybacks ($208M Garrett, $1.2B Royalty Pharma) and deleveraging (Hecla debt -50% YoY to $276M). Period-over-period trends show mixed results: bullish growth in production (Hecla silver +5% YoY, gold +6%) and profitability (Garrett Adj EBIT margin 14.2%), but bearish shifts like Magic Empire revenue -9.8% YoY, JIADE costs tripling to net loss, and Angel Studios Q1 EBITDA loss despite $105-109M revenue prelims. Key developments include Honeywell's separations into three entities (Solstice spun Oct 2025, Aerospace Q3 2026), Hecla full debt redemption unlocking growth capex, and Spire Global's $70M raise for space tech expansion. Portfolio-level patterns reveal proxy-driven governance refreshes (new directors at Honeywell, Remitly), capital flexibility emphasis, and upcoming May 2026 AGMs as catalysts, signaling sector resilience amid macro challenges but with pockets of margin pressure and cash burn.

1 high priority 3 medium 4 total filings

S&P 500 Energy Sector SEC Filings — April 10, 2026

Across the four filings in the S&P 500 Energy intelligence stream, neutral sentiment dominates with Occidental Petroleum's preliminary Q1 2026 realized prices showing oil at 97% of WTI ($69.91/Bbl) but NGL and gas significantly below indices (26% of WTI/NYMEX), signaling pricing weakness outside crude. Devon Energy's pro forma merger financials with Coterra highlight ongoing consolidation in E&P, prepared under Reg S-X with combined 2025 balance sheet and reserves data. Robert Half's DEF 14A reveals sharp 2025 declines (revenues -7% YoY, net income -47% YoY, EPS -45% YoY) amid staffing uncertainty, contrasting energy stability despite its non-core inclusion. Cooke Wealth Management's 13F shows unchanged Q/Q holdings including Chevron ($427k, 2,064 shares), indicating steady institutional conviction in energy majors. No broad insider activity or capital allocation shifts noted, but merger progress and low NGL/gas realizations point to selective opportunities in oil-focused producers amid subdued gas pricing. Sector implications include M&A momentum but pricing pressures capping upside without index recovery.

28 high priority 22 medium 50 total filings

Dow Jones 30 Stocks SEC Filings — April 10, 2026

Across 50 SEC filings from Dow Jones 30-related and associated entities, proxy season dominates with over 25 DEF 14A/DEFA14A filings announcing AGMs in May-June 2026, focusing on director elections, auditor ratifications, and say-on-pay votes, signaling routine governance but potential for activist interventions. Positive themes include M&A accretion (McCormick/Unilever Foods expected EPS uplift Year 1, $600M synergies), corporate restructurings (Honeywell spin-offs completed SOLS Oct 2025, Aerospace Q3 2026), and financings (Annovis $10M for Alzheimer's Phase 3, Spire $70M for space growth). Period-over-period trends show mixed results: VeriSign revenue +6.4% YoY to $1.66B, Voya adj EPS +22% with $775M excess capital, but declines in Magic Empire revenue -9.8% YoY, FRP Q4 net income -77% YoY, EvoAir Q2 revenue -5% YoY. Capital allocation leans toward returns (Voya $374M shareholder returns) and expansions (CoreCivic revolver +$100M to $400M). No widespread insider trading patterns, but strong AGM vote approvals (Biglari 95% turnout, Onfolio 89-97% approvals) indicate shareholder alignment. Key implications: Watch May catalysts for governance shifts, favor growth stories like Voya/VeriSign amid small-cap weakness.

S&P 500 Consumer Discretionary Sector SEC Filings — April 10, 2026

Across 50 filings in the USA S&P 500 Consumer Discretionary stream (broadly including retail, auto, restaurants), proxy statements dominate (over 20 filings) signaling peak AGM season with neutral sentiment, while 13F-HR reports (9 filings) reveal neutral institutional positioning in ETFs and tech giants like Alphabet, Amazon, NVIDIA. Period-over-period trends show mixed results: revenue declines averaging -4% YoY in reporting firms (FGI -1%, Brownie's -8%), but strong growth in outliers like TWFG (+22% revenue, +44% NI) and Voya (>22% adj EPS growth); NOI slight upticks in real estate plays like FRP (+2% total NOI) contrast multifamily declines. M&A/SPAC activity bullish with advancements like Willow Lane EGM on April 30 and Boost Run Nasdaq listing imminent, alongside positive capital raises (e.g., XPLR $232M loan). Forward-looking catalysts cluster in late April-May 2026 AGMs, with limited insider data but board refreshers indicating governance focus. Overall, neutral-to-mixed sentiment (materiality avg 5-6/10) suggests stable consumer disc positioning amid economic uncertainty, favoring SPAC de-SPACs and growth outliers for alpha.

S&P 500 Healthcare Sector SEC Filings — April 10, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (though many span adjacent sectors like financials, energy, and tech), dominant themes include proxy season ramp-up with 20+ DEF 14A/DEFA14A filings highlighting 2025 performance, institutional 13F snapshots showing ETF-heavy portfolios (e.g., S&P 500, Nasdaq premium income), and biotech/pharma revenue pressures offset by clinical wins. Period-over-period trends reveal sharp declines in healthcare biotechs (Akston -99% YoY revenue, Scilex -47% YoY to $30.3M with net loss widening to $374M from $72.8M), contrasted by financial outperformers like Voya (+22% adj EPS, $1B+ earnings) and Velocity (+53.5% net income YoY to $105M). Critical developments: Scilex SP-102 Phase 3 success (p=0.003 primary endpoint), Humana board refresh with healthcare expert, iSpecimen 85% shipping efficiency gain; M&A/capital activity active (Beneficient $8.75M NAV deal, New Era $93.4M offering). Portfolio-level: Margin deterioration in biotechs/pharma (e.g., Octave Insurance Distribution loss to $23.1M from $8.2M), but capital returns strong (News Corp $1B buyback, FREIT $0.10 Q2 dividend); implications favor monitoring May 2026 AGMs for comp/governance votes amid volatility from offerings (Akston IPO, Conexeu direct list).